TYPE 3 DIABETES MELLITUS: BIOLOGICAL MECHANISMS AND ITS RELATIONSHIP WITH ALZHEIMER’S DISEASE
Main Article Content
Abstract
Type 3 diabetes mellitus is an emerging conceptual framework that links metabolic dysfunction with neurodegenerative processes, particularly Alzheimer’s disease. Unlike classical diabetes types that primarily affect peripheral glucose regulation, type 3 diabetes describes insulin resistance and relative insulin deficiency localized within the brain. This impairment disrupts neuronal glucose metabolism, leading to cellular energy deficits, oxidative stress, neuroinflammation, and progressive synaptic dysfunction. Central to this pathology is altered insulin signaling through the PI3K/Akt pathway, which contributes to amyloid-β accumulation, tau hyperphosphorylation, mitochondrial dysfunction, and neuronal loss. Epidemiological evidence indicates that individuals with type 2 diabetes have a significantly elevated risk of developing Alzheimer’s disease, supporting the hypothesis that metabolic and neurodegenerative pathways are closely interconnected. Understanding these mechanisms highlights the importance of insulin sensitivity, metabolic regulation, and anti-inflammatory strategies in preserving cognitive function. Although type 3 diabetes is not yet formally recognized as a clinical diagnosis, growing experimental and clinical data underscore its relevance in explaining Alzheimer’s pathophysiology and guiding future therapeutic approaches. Continued research may open new preventive and treatment strategies aimed at protecting brain health through metabolic intervention.
Downloads
Article Details
Section

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
How to Cite
References
1.Chapple, B., Bayliss, E., Woodfin, S., Smith, M., Winter, J., & Moore, W. (2025). Type 3 Diabetes: Linking Insulin Resistance to Cognitive Decline. Diseases, 13(11), 359. https://doi.org/10.3390/diseases13110359
2.Mittal, K., Jakhmola Mani, R., & Pande Katare, D. (2016). Type 3 Diabetes: Cross Talk between Differentially Regulated Proteins of Type 2 Diabetes Mellitus and Alzheimer’s Disease. Scientific Reports, 6, 25589. https://doi.org/10.1038/srep25589
3.A systematic review on type 3 diabetes: bridging the gap between metabolic dysfunction and Alzheimer’s disease. (2025). Diabetology & Metabolic Syndrome, Article 01930-2. https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-025-01930-2
4.Linking insulin with Alzheimer's disease: emergence as type III diabetes. (2015). Neurological Sciences, 36(10), 1763–1769. https://doi.org/10.1007/s10072-015-2352-5
5.Type 3 Diabetes and Its Role Implications in Alzheimer’s Disease. (n.d.). MDPI International Journal of Molecular Sciences, 21(9), 3165. https://www.mdpi.com/1422-0067/21/9/3165